Sacituzumab govitecan (Trodelvy) has been approved by the FDA as a new option for adults with advanced triple‑negative breast cancer (TNBC), both on its own and together with pembrolizumab (Keytruda), in the first‑line setting. This gives patients and oncologists a new, antibody‑drug conjugate–based backbone in a disease that has historically had very limited treatment choices.
Trodelvy was previously approved for adults with metastatic triple‑negative breast cancer who had already received prior therapies, as well as for certain patients with pre‑treated HR‑positive/HER2‑negative breast cancer. Those earlier approvals were based on studies showing Trodelvy could shrink tumors and extend the time before the cancer grew in heavily pre‑treated patients, helping establish it as an important option in later‑line settings before this new first‑line approval.
Who this approval is for
- Trodelvy alone can now be used as the first treatment for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD‑1 or PD‑L1 inhibitor–based therapy.
- Trodelvy plus pembrolizumab (or pembrolizumab plus the subcutaneous formulation, Keytruda Qlex) can be used as the first treatment for adults with unresectable locally advanced or metastatic TNBC whose tumors are PD‑L1 positive with a combined positive score (CPS) of 10 or higher, using an FDA‑authorized PD‑L1 test.
- These approvals are based on two phase 3 clinical trials: ASCENT‑03 (Trodelvy alone) and ASCENT‑04/KEYNOTE‑D19 (Trodelvy plus pembrolizumab).
What the trials showed
Trodelvy alone (ASCENT‑03)
- The study enrolled 558 people with advanced TNBC who had not received prior treatment for metastatic disease and were not candidates for immunotherapy.
- Patients were randomly assigned to receive either Trodelvy or a physician’s choice of standard chemotherapy (nab‑paclitaxel, paclitaxel, or gemcitabine plus carboplatin).
- Trodelvy significantly delayed tumor growth or spread:
- Median progression‑free survival (PFS) was 9.7 months with Trodelvy vs 6.9 months with standard chemo (hazard ratio 0.62; p<0.0001).
- The tumor response rate (how many patients had their tumors shrink) was similar in both groups (about 50% vs 47%), but Trodelvy kept responses going longer and delayed progression more effectively.
- Overall survival data are not yet mature, meaning it is too early for a firm conclusion about whether patients live longer, though trends are being followed.
Trodelvy plus pembrolizumab (ASCENT‑04/KEYNOTE‑D19)
- This trial enrolled 443 people with advanced TNBC whose tumors were PD‑L1 CPS ≥10 and who had not received prior systemic therapy for advanced disease.
- Participants were randomized to:
- Trodelvy + pembrolizumab, or
- Standard chemotherapy (nab‑paclitaxel, paclitaxel, or gemcitabine/carboplatin) + pembrolizumab.
- The Trodelvy + pembrolizumab combination also significantly delayed tumor growth or spread:
- Median PFS 11.2 months vs 7.8 months with chemo + pembrolizumab (hazard ratio 0.65; p=0.0009).
- The response rate was higher with the Trodelvy combo:
- 61% vs 55% with chemo + pembrolizumab.
- As with ASCENT‑03, overall survival data are still immature, so longer follow‑up is needed to see the full impact on how long patients live.
Safety and side effects patients should know about
Trodelvy
- The prescribing information includes a boxed warning (the strongest FDA safety warning) for:
- Severe diarrhea
- Severe neutropenia (very low white blood cell counts that increase infection risk)
- Other important warnings and precautions include:
- Hypersensitivity and infusion‑related reactions
- Nausea and vomiting
- Higher risk of certain side effects in patients with reduced UGT1A1 activity (a genetic factor that affects drug metabolism)
- Embryo‑fetal toxicity – Trodelvy can harm an unborn baby; effective contraception is critical.
Pembrolizumab / Keytruda Qlex
- Pembrolizumab is an immunotherapy, and its label highlights the risk of immune‑mediated side effects, where the immune system attacks normal organs:
- These can affect the lungs, liver, intestines, endocrine glands (like thyroid), skin, and other organs.
- Other warnings include:
- Infusion‑related reactions
- Complications after allogeneic stem cell transplantation
- Embryo‑fetal toxicity
Patients on these treatments are monitored closely with blood tests, symptom checks, and imaging. It is very important to report new symptoms promptly—especially diarrhea, fevers, shortness of breath, worsening fatigue, or signs of infection.
What this means for people with TNBC
- For patients who cannot receive immunotherapy, Trodelvy alone is now an FDA‑approved first‑line option that outperformed several standard chemotherapy regimens in delaying disease progression.
- For patients with PD‑L1 CPS ≥10, Trodelvy combined with pembrolizumab offers a new immunotherapy‑based backbone that kept the cancer controlled longer than pembrolizumab plus standard chemotherapy.
- Overall survival data are still developing, but these approvals reflect a meaningful step forward in a historically hard‑to‑treat subtype of breast cancer.
Reference
